comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 10:06:20 - browse：1

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： CRISPR technology availability, affordability needs to be expanded

explore

leisure time

WSS

Crinetics acromegaly drug succeeds in late

How to fix cancer clinical trials' diversity problem

How to fix cancer clinical trials' diversity problem

What American doctors can learn from their Israeli counterparts

How to fix cancer clinical trials' diversity problem

ALS advocates say criticism of new drugs misses bigger picture

focus

comprehensive

focus

Trump demands the U.S. pay no more for drugs than other countries … again

With Wegovy coverage, Medicare patients may face high costs

Dobbs anniversary: the lost opportunity of abortion as health care

6 surprising facts about sugar

The high cost of giving birth even with insurance

U.K. officials, researchers try to ease path for bespoke genetic treatments

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why Novartis is changing the name of its research labs

In Memoriam: Notable people who died in 2023

CRISPR technology availability, affordability needs to be expanded

entertainment

Listen: Biogen's potential pivot, & Illumina's next chapter

This gene therapy has record $4.25 million price. It's saved children.

Biotech investment managers search for lucrative opportunities

How to protect patients from sexual assault

With Wegovy coverage, Medicare patients may face high costs

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

focus

explore

leisure time

focus